As discussions and the hype surrounding CRISPR’s (clustered regularly interspaced short palindromic repeats) potential applications increase, so do the legal and financial risks. Hailed as the biggest biological advancement since the polymerase chain reaction, the controversial, yet revolutionary, gene editing tool is now at the center of a major patent dispute over who owns the rights to exploit it commercially.

The battle, a testament to the high-stakes game of biotech investing, could make or break some businesses. With several startups looking to capitalize on the new method and some existing companies abandoning time-perfected techniques in favor of the cheaper, faster, easier option, this breakthrough technology has attracted hundreds of millions of dollars in investments and licensing deals.

Please join us on Friday, June 24, 2016, for Navigating the CRISPR Patent Landscape and Business Impact, a web conference analyzing the key intellectual property complexities and investment risks surrounding this disruptive technology and offering tips for doing business in the space despite them.

Discussion Topics

• What is CRISPR?

• Recently issued CRISPR patents

• Claim types being granted in CRISPR patents

• Interference proceedings and other potential entanglement situations involving CRISPR patents

• Investing in biotech companies in the face of CRISPR disputes

• Viable applications and business opportunities, including licensing and collaboration